Newsroom

Sorted by: Latest

-

Incyte präsentiert auf der ASH 2026 neue Daten, die die Fortschritte im gesamten hämatologischen Portfolio verdeutlichen

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) gab heute bekannt, dass neue Daten, die die Fortschritte im gesamten hämatologischen Portfolio des Unternehmens beleuchten, in mehr als 30 Abstracts auf der Jahrestagung 2026 der American Society of Hematology (ASH) vorgestellt werden, die vom 12. bis 15. Dezember 2026 in New Orleans stattfindet. „Unsere ASH-Präsentationen belegen bedeutende Fortschritte in unserem gesamten Hämatologie-Portfolio, um neuartige Behandlungsansätze für Mensch...
-

EoS Fitness Celebrates Record $250,000 Fundraising Milestone for Challenged Athletes Foundation at Sold-Out Tour de Cove

DALLAS & SAN DIEGO--(BUSINESS WIRE)--EoS Fitness turned a sold-out Tour de Cove into a $250,000 fundraising milestone for its premier charitable partner, Challenged Athletes Foundation....
-

Incyte présentera de nouvelles données illustrant les avancées de son portefeuille en hématologie à l'ASH 2026

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) annonce aujourd’hui que de nouvelles données illustrant les avancées de son portefeuille en hématologie seront présentées dans plus de 30 résumés lors du congrès annuel 2026 de l’American Society of Hematology (ASH), qui se tiendra du 12 au 15 décembre 2026 à La Nouvelle-Orléans. « Nos présentations à l’ASH témoignent d’avancées significatives dans l’ensemble de notre portefeuille d’hématologie, au service de nouvelles approches thérap...
-

AM Best Assigns Credit Ratings to Nuclear Industry Reinsurance Association

AMSTERDAM--(BUSINESS WIRE)--AM Best has assigned a Financial Strength Rating of B++ (Good) and a Long-Term Issuer Credit Rating of “bbb+” (Good) to Nuclear Industry Reinsurance Association (NIRA) (Luxembourg). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect NIRA’s balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management. NIRA’s balance sheet s...
-

Samenvatting: Incyte presenteert nieuwe gegevens die de vorderingen aantonen in zijn hematologieportfolio op ASH 2026

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) maakte vandaag bekend dat nieuwe gegevens die de vorderingen in zijn hematologieportfolio aantonen, in meer dan 30 samenvattingen zullen worden voorgestelde tijdens de 2026 ASH (American Society of Hematology) Annual Meeting, die van 12 tot 15 december 2026 doorgaat in New Orleans. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de br...
-

BREAKING NEWS: SourceNow VMS Named Healthcare Workforce Management Software of the Year 2026!

POMPANO BEACH, Fla.--(BUSINESS WIRE)--Jean-Paul Renard, CEO, SourceNow, announced, "I'm incredibly proud to share that Healthcare Tech Outlook has recognized SourceNow VMS as Healthcare Workforce Management Software of the Year 2026, featuring our company in an independently published article titled 'Turning Workforce Strategy into Measurable Savings.'" This recognition represents something much bigger than software. For years, the workforce management industry has focused on technology, transa...
-

SBSB Earns Top-Tier Honors From Best Law Firms 2027

HOUSTON--(BUSINESS WIRE)--Schouest, Bamdas, Soshea & BenMaier PLLC (SBSB) has been selected as one of the nation’s top law firms for admiralty and maritime law by Best Law Firms, one of the industry’s oldest and most respected legal guides. The firm earned a Tier 1 ranking — the highest possible — for admiralty and maritime law nationally and in the Houston metro area. SBSB also received a top-tier ranking for personal injury and product liability defense in Dallas-Fort Worth and was recogn...
-

Resumen: Incyte presentará nuevos datos que destacan los avances en toda su cartera de productos hematológicos en ASH 2026

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) ha anunciado hoy que se presentarán nuevos datos que destacan los avances en toda su cartera de productos hematológicos en más de 30 ponencias en 2026 American Society of Hematology (ASH) Annual Meeting, que se celebrará del 12 al 15 de diciembre de 2026 en Nueva Orleans. El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el texto...
-

A Year in Travel 2026: Las Vegas Tops American Travelers’ Bookings as Tokyo Leads the Wish List for 2027

LONDON--(BUSINESS WIRE)--eDreams ODIGEO - the world’s leading travel subscription platform and parent company of eDreams in the US - launches its annual ‘A Year in Travel’ report today. It draws on search and booking data from American travellers highlighting evolving 2026 travel trends, and a sneak peek at 2027. Where Americans went in 2026 Domestic destinations dominated American travel in 2026. Las Vegas claimed the top spot for bookings, ahead of Florida favorites Orlando and Fort Lauderdal...
-

Trained Therapeutix Discovery任命Andrew Glass為執行長

達拉斯與荷蘭奧斯--(BUSINESS WIRE)--(美國商業資訊)-- 免疫療法領域的領導者Trained Therapeutix Discovery(簡稱TTxD)由Jean Boulle Group和Heritage Group創辦,專注於開發用於調節先天免疫的奈米藥物。該公司宣布任命Andrew Glass為執行長,即刻生效。Glass先生在生命科學產業擁有超過20年的領導經驗,曾任Vivasure Medical執行長,此前在Abbott擔任高階領導職務超過15年。 繼今年稍早宣布公司董事會人事變動後,Glass先生的加入正值公司從臨床前轉型為臨床階段之際。他在研發策略、融資和組織發展方面的專長,將協助公司加速實現與TTxD專有的RIDE平台技術相關的目標,包括拓展免疫學和炎症計畫,例如提名RIDE-002的臨床候選藥物,以及持續維護與利害關係人的關係,以確保未來的發展機會。 TTxD董事長Stefano Buono表示: 「我謹代表董事會,熱烈歡迎Andrew Glass在公司發展的關鍵時刻加入,他在構建和擴展創新生命科學領域的卓越成就將成為公司的寶貴財富。他在TTxD領...